인보사 세포 중 하나가 최초 임상 시 승인됐던 세포가 아닌 다른 세포를 기반으로 한 사실이 밝혀지며 국내에서는 허가 취소됐다.
The license was revoked in Korea after one of the Invossa cells was found to be based on a cell other than one that was initially approved during clinical trials.